Evaluation of the effectiveness of Curcumin on fatty liver disease in childre

Phase 3

• Conditions: AFLD.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20170628034786N4
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 12 July 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Non-alcoholic fatty liver disease confirmed by a pediatric gastroenterologist
Patient parents' consent to participate in this project

Exclusion Criteria

Allergy to curcumin

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of Alanine aminotransferase. Timepoint: 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of liver transaminase.;Serum level of Aspartate aminotransferase. Timepoint: 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of liver transaminase.

Secondary Outcome Measures

Name	Time	Method
Body mass index. Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Measurement of height and weight and ratio of weight to square of height.;Fasting Blood Sugar. Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of serum Fasting Blood Sugar.;Lipid profile(Chol,TG,HDL,LDL). Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of serum lipid profile(Chol, TG, HDL,LDL).;Alkaline phosphatase. Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of serum Alkaline phosphatase.